RESONIUM A Powder Ref.[10832] Active ingredients: Polystyrene sulfonate

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK

5.1. Pharmacodynamic properties

Resonium A is a cation exchange resin for the treatment of hyperkalaemia.

5.2. Pharmacokinetic properties

Ion exchange resins with a particle size ranging from 5-10 micrometres (as in Resonium A) are not absorbed from the gastro-intestinal tract and are wholly excreted in the faeces.

5.3. Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.